Payload Information
General Information of This Payload
| Payload ID | PAY0PQZBT |
|||||
|---|---|---|---|---|---|---|
| Name | Tubulin inhibitor C |
|||||
| Synonyms |
Tubulin inhibitor C
Click to Show/Hide
|
|||||
| Target | Microtubule (MT) | |||||
| Structure |
|
|||||
| Formula | C40H68N8O6 |
|||||
| Isosmiles | CC([C@H](N(C)C)C(N[C@@H](C(C)C)C(N(C)[C@H]([C@H](OC)CC(N1CCC[C@H]1[C@H](OC)[C@H](C(N[C@H](CN=[N+]=[N-])CC2=CC=CC=C2)=O)C)=O)[C@H](CC)C)=O)=O)C |
|||||
| InChI |
InChI=1S/C40H68N8O6/c1-13-27(6)36(47(10)40(52)34(25(2)3)44-39(51)35(26(4)5)46(8)9)32(53-11)23-33(49)48-21-17-20-31(48)37(54-12)28(7)38(50)43-30(24-42-45-41)22-29-18-15-14-16-19-29/h14-16,18-19,25-28,30-32,34-37H,13,17,20-24H2,1-12H3,(H,43,50)(H,44,51)/t27-,28+,30-,31-,32+,34-,35-,36-,37+/m0/s1
|
|||||
| InChIKey |
UDCOBVFNMMKZOF-UUFHNPECSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
757.034 |
Polar area |
169.28 |
||
Complexity |
1321.005721 |
xlogp Value |
4.6715 |
|||
Heavy Count |
54 |
Rot Bonds |
22 |
|||
Hbond acc |
8 |
Hbond Donor |
2 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
CA2975383C example65 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.1 nM
|
Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.117 nM
|
Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.158 nM
|
Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
4.762 nM
|
Moderate XXX expression (XXX++) | ||
| Method Description |
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-453 cells | CVCL_0418 | ||
CA2975383C example19 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.156 nM
|
Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.193 nM
|
Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.232 nM
|
Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.34 nM
|
Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | SKOV-3 cells | CVCL_0532 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
3.946 nM
|
Moderate XXX expression (XXX++) | ||
| Method Description |
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-453 cells | CVCL_0418 | ||